How splicing confers treatment resistance in prostate cancer

Prathyusha Konda; Srinivas R Viswanathan

doi:10.7554/eLife.82070

How splicing confers treatment resistance in prostate cancer

Elife. 2022 Aug 23:11:e82070. doi: 10.7554/eLife.82070.

Authors

Prathyusha Konda¹, Srinivas R Viswanathan¹

Affiliation

¹ Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.

Abstract

A splice variant of the androgen receptor that drives prostate cancer resistance translocates into the nucleus using a different mechanism from the full-length receptor and exhibits distinct molecular properties once inside.

Keywords: AR-V7; androgen receptor; cancer biology; human; intranuclear mobility; nuclear import; prostate cancer; transcriptional activity.

Publication types

Editorial

MeSH terms

Gene Expression Regulation, Neoplastic
Humans
Male
Prostatic Neoplasms, Castration-Resistant* / genetics
Protein Isoforms / metabolism
RNA Splicing
Receptors, Androgen / genetics
Receptors, Androgen / metabolism

Substances

Protein Isoforms
Receptors, Androgen